\nTriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the \u201cCompany\u201d), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of Richard Marshall, M.D., as Chief Medical Officer on a full-time basis, effective June 29, 2026. Dr. Marshall will transition into the role from his current position as Medical Director, a role he has held since January 2025. In his new capacity, he will lead the Company\u2019s medical strategy and provide clinical leadership across development, evidence generation and broader strategic initiatives.<\/p>\n
\n\u201cDr. Marshall brings a rare combination of frontline clinical insight and deep interventional oncology expertise that is uniquely aligned with our mission. Since joining TriSalus as Medical Director, he has been an invaluable clinical voice in driving the expansion of our TriNav product suite and proprietary Pressure-Enabled Drug Delivery (\u201cPEDD\u201d) platform across a broad range of indications beyond the liver,\u201d said Mary Szela, President and Chief Executive Officer of TriSalus. \u201cAs we continue to see strong physician engagement, utilization and interest in the PEDD platform, Dr. Marshall’s appointment as Chief Medical Officer positions us to accelerate the advancement of our clinical and economic advantages data and deliver meaningful impact for patients.\u201d<\/p>\n
\nDr. Marshall is an interventional radiologist with extensive experience spanning interventional oncology, hepatobiliary interventions and trauma care. After graduating from Tulane University School of Medicine, he completed his diagnostic radiology residency at Ochsner Clinic Foundation, where he served as Chief Resident, followed by fellowship training in interventional radiology and interventional oncology at Weill Cornell University and Memorial Sloan Kettering Cancer Center in New York. He joined the faculty at Louisiana State University Health Sciences Center and then Tulane University, both in New Orleans.<\/p>\n
\nDuring his time at LSU Health Sciences Center, Dr. Marshall developed Louisiana\u2019s first Interventional Radiology Residency and led a high-volume clinical practice focused on interventional oncology, hepatobiliary interventions and trauma care. Since 2021, he has also served at Tulane University School of Medicine, where he has remained active in medical student and resident education. His clinical experience has included care for patients undergoing organ transplantation, pediatric interventions, embolization for thyroid disease and uterine fibroids, musculoskeletal pain palliation, venous interventions and palliative care.<\/p>\n
\n\u201cI am honored to step into the Chief Medical Officer role at TriSalus at this important time for the Company,\u201d said Dr. Marshall. \u201cTriSalus is working to address significant challenges in the treatment of liver and pancreatic tumors to provide meaningful benefits to patients. I look forward to helping advance the Company\u2019s medical and clinical efforts as we continue to build on the potential of the PEDD approach and support better and safer patient outcomes.\u201d<\/p>\n
\nDr. Marshall\u2019s appointment reflects TriSalus\u2019 continued focus on strengthening its leadership team as the Company advances its PEDD platform, which combines its drug delivery technology with therapeutic development efforts aimed at improving outcomes for patients with solid tumors.<\/p>\n
About TriSalus Life Sciences<\/b><\/p>\n
\nTriSalus Life Sciences\u00ae<\/sup> is an oncology focused medical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company\u2019s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company\u2019s three FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery\u2122 (PEDD) approach to deliver a range of therapeutics: the TriNav\u00ae<\/sup> Infusion System and TriNav Infusion System LV for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. The PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company\u2019s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology\u2122 (PERIO) clinical trials support the hypothesis that nelitolimod delivered via the PEDD technology may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by the PEDD technology are commonly present as well. The Company is in the final stages of data completion for a number of phase 1 clinical trials and will begin exploring partnership opportunities for development.<\/p>\n Forward Looking Statements<\/b><\/p>\n \nStatements made in this press release regarding matters that are not historical facts are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward\u2010looking statements. Such statements include, but are not limited to, statements regarding fourth quarter 2025 and full year 2025 financial results and 2026 financial outlook and future profitability, cash flows, and the Company\u2019s ability to execute on its strategy. Risks that could cause actual results to differ from those expressed in these forward\u2010looking statements include the risk that the Company will not become profitable on its expected timeline, if at all, the risk that the reported financial results will differ from the estimates provided in this press release, risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates, including that future clinical results may not be consistent with patient data generated during the Company\u2019s clinical trials, the cost and timing of all development activities and clinical trials, unexpected safety and efficacy data observed during clinical studies, the risks associated with the credit facility, including the Company\u2019s ability to remain in compliance with all its obligations thereunder to avoid an event of default, the risk that the Company will continue to raise capital through the issuance and sale of its equity securities to fund its operations, the risk that the Company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility, changes in expected or existing competition or market conditions, changes in the regulatory environment, unexpected litigation or other disputes, unexpected expensed costs, made in this press release regarding matters that are not historical facts are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward\u2010looking statements. Such statements include, but are not limited to, statements regarding the benefits and potential benefits of the Company\u2019s PEDD drug delivery technology, TriNav\u00ae<\/sup> system and nelitolimod investigational immunotherapy, and the Company\u2019s ability to execute on its strategy. Risks that could cause actual results to differ from those expressed in these forward\u2010looking statements include risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates, including that future clinical results may not be consistent with patient data generated during the Company\u2019s clinical trials, the cost and timing of all development activities and clinical trials, unexpected safety and efficacy data observed during clinical studies, the risks associated with the credit facility, including the Company\u2019s ability to remain in compliance with all its obligations thereunder to avoid an event of default, the risk that the Company will continue to raise capital through the issuance and sale of its equity securities to fund its operations, the risk that the Company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility, the risk that the Company will not become profitable on its expected timeline, if at all, the risk that the reported financial results will differ from the estimates provided in this press release, changes in expected or existing competition or market conditions, changes in the regulatory environment, unexpected litigation or other disputes, unexpected expensed costs, and other risks described in the Company\u2019s filings with the Securities and Exchange Commission under the heading \u201cRisk Factors.\u201d All forward\u2010looking statements contained in this press release speak only as of the date on which they were made and are based on management\u2019s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made except as required by law.<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260407456236\/en\/<\/a><\/span><\/p>\n For Media Inquiries:<\/p>\n
\n<\/b>
Jeremy Feffer, Managing Director
\n
LifeSci Advisors
\n
212.915.2568
\n
jfeffer@lifesciadvisors.com<\/a><\/p>\n